FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Thomas Chase

Research Profile

Disorders

Chemicals & Drugs

Living Beings

Anatomy

Co-author Network

Publications

TOP 3
Kimberly E Vanover; Adrienne J Betz; Suzanne M Weber; Francesco Bibbiani; Aiste Kielaite; David M Weiner; Robert E Davis; Thomas N Chase; John D Salamone
A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model.
Zhong-Qin Liang; Yun-Lin Li; Xi-Lin Zhao; Rong Han; Xiao-Xia Wang; Yumei Wang; Thomas N Chase; M Catherine Bennett; Zheng-Hong Qin
NF-kappaB contributes to 6-hydroxydopamine-induced apoptosis of nigral dopaminergic neurons through p53.
Zhong-Qin Liang; Xiaoxia Wang; Ling-Yun Li; Yumei Wang; Ren-Wu Chen; De-Maw Chuang; Thomas N Chase; Zheng-Hong Qin
Nuclear factor-kappaB-dependent cyclin D1 induction and DNA replication associated with N-methyl-D-aspartate receptor-mediated apoptosis in rat striatum.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Thomas Chase (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2008: Kimberly E Vanover; Adrienne J Betz; Suzanne M Weber; Francesco Bibbiani; Aiste Kielaite; David M Weiner; Robert E Davis; Thomas N Chase; John D Salamone
A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model.
Pharmacology, biochemistry, and behavior 2008;90(4):540-4.
2007: Zhong-Qin Liang; Yun-Lin Li; Xi-Lin Zhao; Rong Han; Xiao-Xia Wang; Yumei Wang; Thomas N Chase; M Catherine Bennett; Zheng-Hong Qin
NF-kappaB contributes to 6-hydroxydopamine-induced apoptosis of nigral dopaminergic neurons through p53.
Brain research 2007;1145():190-203.
2007: Zhong-Qin Liang; Xiaoxia Wang; Ling-Yun Li; Yumei Wang; Ren-Wu Chen; De-Maw Chuang; Thomas N Chase; Zheng-Hong Qin
Nuclear factor-kappaB-dependent cyclin D1 induction and DNA replication associated with N-methyl-D-aspartate receptor-mediated apoptosis in rat striatum.
Journal of neuroscience research 2007;85(6):1295-309.
2007: C P S Smith; Justin D Oh; Francesco Bibbiani; M A Collins; I Avila; Thomas N Chase
Tamoxifen effect on L-DOPA induced response complications in parkinsonian rats and primates.
Neuropharmacology 2007;52(2):515-26.
2006: William Bara-Jimenez; Tzvetelina Dimitrova; Abdullah Sherzai; Murat Aksu; Thomas N Chase
Glutamate release inhibition ineffective in levodopa-induced motor complications.
Movement disorders : official journal of the Movement Disorder Society 2006;21(9):1380-3.
2006: Gerda Andringa; John G J M Bol; Xiaoxia Wang; Amber J Boekel; M Catherine Bennett; Thomas N Chase; Benjamin Drukarch
Changed distribution pattern of the constitutive rather than the inducible HSP70 chaperone in neuromelanin-containing neurones of the Parkinsonian midbrain.
Neuropathology and applied neurobiology 2006;32(2):157-69.
2005: Francesco Bibbiani; Justin D Oh; A Kielaite; M A Collins; C Smith; Thomas N Chase
Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD.
Experimental neurology 2005;196(2):422-9.
2005: Zhong-Qin Liang; Xiao-Xia Wang; Yumei Wang; De-Maw Chuang; Marian DiFiglia; Thomas N Chase; Zheng-Hong Qin
Susceptibility of striatal neurons to excitotoxic injury correlates with basal levels of Bcl-2 and the induction of P53 and c-Myc immunoreactivity.
Neurobiology of disease 2005;20(2):562-73.
2005: William Bara-Jimenez; Francesco Bibbiani; Michael J Morris; Tzvetelina Dimitrova; Abdullah Sherzai; M Maral Mouradian; Thomas N Chase
Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2005;20(8):932-6.
2005: Hui-Ling Zhang; Zhi Hong Huang; Yi Zhu; Zhong-Qin Liang; Rong Han; Xiao-Xia Wang; Thomas N Chase; Zheng-Hong Qin
Neuroprotective effects of prostaglandin A1 in animal models of focal ischemia.
Brain research 2005;1039(1-2):203-6.
2005: Francesco Bibbiani; Lauren C Costantini; Raj Patel; Thomas N Chase
Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates.
Experimental neurology 2005;192(1):73-8.
2004: William Bara-Jimenez; Tzvetelina Dimitrova; Abdullah Sherzai; Antonella Favit; M Maral Mouradian; Thomas N Chase
Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 2004;19(10):1183-6.
2004: R H Wessell; S M Ahmed; Frank Menniti; G L Dunbar; Thomas N Chase; Justin D Oh
NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats.
Neuropharmacology 2004;47(2):184-94.
2004: Thomas N Chase
Striatal plasticity and extrapyramidal motor dysfunction.
Parkinsonism & related disorders 2004;10(5):305-13.
2004: Gerda Andringa; K Y Lam; M Chegary; Xiaoxia Wang; Thomas N Chase; M Catherine Bennett
Tissue transglutaminase catalyzes the formation of alpha-synuclein crosslinks in Parkinson's disease.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2004;18(7):932-4.
2003: Thomas N Chase; Francesco Bibbiani; William Bara-Jimenez; Tzvetelina Dimitrova; J D Oh-Lee
Translating A2A antagonist KW6002 from animal models to parkinsonian patients.
Neurology 2003;61(11 Suppl 6):S107-11.
2003: Hiroshi Kase; Shiro Aoyama; Michio Ichimura; Ken Ikeda; A Ishii; T Kanda; Kumiko Koga; N Koike; Masako Kurokawa; Yoshihisa Kuwana; Akihisa Mori; J Nakamura; Hiromi Nonaka; Mayumi Ochi; Mayumi Saki; J Shimada; Tomomi Shindou; Shizuo Shiozaki; F Suzuki; M Takeda; K Yanagawa; Peter J Richardson; Peter Jenner; P Bedard; Emiliana Borrelli; Robert A Hauser; Thomas N Chase
Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease.
Neurology 2003;61(11 Suppl 6):S97-100.
2003: Francesco Bibbiani; Justin D Oh; Jacobus P Petzer; Neal Castagnoli; Jiang-Fan Chen; Michael A Schwarzschild; Thomas N Chase
A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease.
Experimental neurology 2003;184(1):285-94.
2003: Gerda Andringa; Fu Du; Thomas N Chase; M Catherine Bennett
Mapping of rat brain using the Synuclein-1 monoclonal antibody reveals somatodendritic expression of alpha-synuclein in populations of neurons homologous to those vulnerable to Lewy body formation in human synucleopathies.
Journal of neuropathology and experimental neurology 2003;62(10):1060-75.
2003: William Bara-Jimenez; Abdullah Sherzai; Tzvetelina Dimitrova; Antonella Favit; Francesco Bibbiani; M Gillespie; Michael J Morris; M Maral Mouradian; Thomas N Chase
Adenosine A(2A) receptor antagonist treatment of Parkinson's disease.
Neurology 2003;61(3):293-6.
2003: Justin D Oh; Karnon Chartisathian; Syed M Ahmed; Thomas N Chase
Cyclic AMP responsive element binding protein phosphorylation and persistent expression of levodopa-induced response alterations in unilateral nigrostriatal 6-OHDA lesioned rats.
Journal of neuroscience research 2003;72(6):768-80.
2003: Pierre J Blanchet; Spiros Konitsiotis; Hideki Mochizuki; Ryszard Pluta; Dwaine F Emerich; Thomas N Chase; M Maral Mouradian
Complications of a trophic xenotransplant approach in parkinsonian monkeys.
Progress in neuro-psychopharmacology & biological psychiatry 2003;27(4):607-12.
2003: Justin D Oh; Alfred I Geller; Guo rong Zhang; Thomas N Chase
Gene transfer of constitutively active protein kinase C into striatal neurons accelerates onset of levodopa-induced motor response alterations in parkinsonian rats.
Brain research 2003;971(1):18-30.
2003: Thomas N Chase; Francesco Bibbiani; Justin D Oh
Striatal glutamatergic mechanisms and extrapyramidal movement disorders.
Neurotoxicity research 2003;5(1-2):139-46.
2003: Pierre J Blanchet; Leo Verhagen Metman; Thomas N Chase
Renaissance of amantadine in the treatment of Parkinson's disease.
Advances in neurology 2003;91():251-7.
2002: Xiaoxia Wang; Zheng-Hong Qin; Yan Leng; Yumei Wang; Xiannu Jin; Thomas N Chase; M Catherine Bennett
Prostaglandin A1 inhibits rotenone-induced apoptosis in SH-SY5Y cells.
Journal of neurochemistry 2002;83(5):1094-102.
2002: Alessandro Tessitore; Ahmad R Hariri; Francesco Fera; William G Smith; Thomas N Chase; Thomas M Hyde; Daniel R Weinberger; Venkata S Mattay
Dopamine modulates the response of the human amygdala: a study in Parkinson's disease.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2002;22(20):9099-103.
2002: Justin D Oh; Francesco Bibbiani; Thomas N Chase
Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models.
Experimental neurology 2002;177(2):557-64.
2002: L Verhagen Metman; Michael J Morris; C Farmer; M Gillespie; K Mosby; Joanne Wuu; Thomas N Chase
Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine.
Neurology 2002;59(5):694-9.
2002: Keith Jeffries; C Schooler; C Schoenbach; Peter Herscovitch; Thomas N Chase; Allen R Braun
The functional neuroanatomy of Tourette's syndrome: an FDG PET study III: functional coupling of regional cerebral metabolic rates.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2002;27(1):92-104.
2002: Venkata S Mattay; Alessandro Tessitore; Joseph Callicott; Alessandro Bertolino; Terry Goldberg; Thomas N Chase; Thomas M Hyde; Daniel R Weinberger
Dopaminergic modulation of cortical function in patients with Parkinson's disease.
Annals of neurology 2002;51(2):156-64.
2002: Justin D Oh; Thomas N Chase
Glutamate-mediated striatal dysregulation and the pathogenesis of motor response complications in Parkinson's disease.
Amino acids 2002;23(1-3):133-9.
2001: Francesco Bibbiani; Justin D Oh; Thomas N Chase
Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models.
Neurology 2001;57(10):1829-34.
2001: Yan Leng; Thomas N Chase; M Catherine Bennett
Muscarinic receptor stimulation induces translocation of an alpha-synuclein oligomer from plasma membrane to a light vesicle fraction in cytoplasm.
The Journal of biological chemistry 2001;276(30):28212-8.
2001: Paolo Del Dotto; Nicola Pavese; Gianna Gambaccini; Silvia Bernardini; Leo Verhagen Metman; Thomas N Chase; Ubaldo Bonuccelli
Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study.
Movement disorders : official journal of the Movement Disorder Society 2001;16(3):515-20.
2001: JT Hutton; Leo Verhagen Metman; Thomas N Chase; Jorge L Juncos; William Koller; Rajesh Pahwa; Peter LeWitt; A Samii; J K Tsui; Donald B Calne; C H Waters; V P Calabrese; J P Bennett; R Barrett; J L Morris
Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebo-controlled study.
Movement disorders : official journal of the Movement Disorder Society 2001;16(3):459-63.
2001: Leo Verhagen Metman; M Gillespie; C Farmer; Francesco Bibbiani; Spiros Konitsiotis; M Morris; Holly A Shill; William Bara-Jimenez; M Maral Mouradian; Thomas N Chase
Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease.
Clinical neuropharmacology 2001;24(3):163-9.
2001: Zheng-Hong Qin; Yumei Wang; Ren-Wu Chen; Xiaoxia Wang; Ming Ren; De-Maw Chuang; Thomas N Chase
Prostaglandin A(1) protects striatal neurons against excitotoxic injury in rat striatum.
The Journal of pharmacology and experimental therapeutics 2001;297(1):78-87.
2001: Ira Shoulson; J Penney; M McDermott; S Schwid; E Kayson; Thomas N Chase; Stanley Fahn; J Timothy Greenamyre; Anthony E Lang; A Siderowf; N Pearson; M Harrison; E Rost; A Colcher; M Lloyd; M Matthews; Rajesh Pahwa; D McGuire; M F Lew; S Schuman; Kenneth Marek; S Broshjeit; Stewart A Factor; D Brown; A Feigin; J Mazurkiewicz; B Ford; D Jennings; S Dilllon; C Comella; L Blasucci; K Janko; Lisa M Shulman; W Wiener; D Bateman-Rodriguez; A Carrion; O Suchowersky; A L Lafontaine; C Pantella; E Siemers; J Belden; R Davies; M Lannon; D Grimes; P Gray; W Martin; L Kennedy; Charles H Adler; S Newman; John P Hammerstad; C Stone; Peter LeWitt; K Bardram; K Mistura; J Miyasaki; L Johnston; Jang-Ho Cha; M Tennis; M Panniset; J Hall; J Tetrud; J Friedlander; Robert A Hauser; L Gauger; R Rodnitzky; A Deleo; J Dobson; L Seeberger; C Dingmann; D Tarsy; P Ryan; L Elmer; D Ruzicka; M Stacy; M Brewer; B Locke; D Baker; C Casaceli; D Day; M Florack; K Hodgeman; N Laroia; R Nobel; C Orme; L Rexo; K Rothenburgh; K Sulimowicz; A Watts; E Wratni; Pierre N. Tariot; Christopher Cox; C Leventhal; V Alderfer; A M Craun; J Frey; L McCree; J McDermott; J Cooper; T Holdich; B Read
A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease.
Neurology 2001;56(4):455-62.
2001: Thomas N Chase; Spiros Konitsiotis; Justin D Oh
Striatal molecular mechanisms and motor dysfunction in Parkinson's disease.
Advances in neurology 2001;86():355-60.
2000: Thomas N Chase; Justin D Oh
Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism.
Trends in neurosciences 2000;23(10 Suppl):S86-91.
2000: Concepció Marin; Anna Jimenez; Mercè Bonastre; Thomas N Chase; Eduardo Tolosa
Non-NMDA receptor-mediated mechanisms are involved in levodopa-induced motor response alterations in Parkinsonian rats.
Synapse (New York, N.Y.) 2000;36(4):267-74.
2000: Spiros Konitsiotis; Pierre J Blanchet; L Verhagen; E Lamers; Thomas N Chase
AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys.
Neurology 2000;54(8):1589-95.
2000: Thomas N Chase; Justin D Oh; Spiros Konitsiotis
Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms.
Journal of neurology 2000;247 Suppl 2():II36-42.
2000: Thomas N Chase; Justin D Oh
Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications.
Annals of neurology 2000;47(4 Suppl 1):S122-9; discussion S129-30.
2000: M Nakai; Z Qin; Yumei Wang; Thomas N Chase
NMDA and non-NMDA receptor-stimulated IkappaB-alpha degradation: differential effects of the caspase-3 inhibitor DEVD.CHO, ethanol and free radical scavenger OPC-14117.
Brain research 2000;859(2):207-16.
2000: M Nakai; Zheng-Hong Qin; Jiang-Fan Chen; Yumei Wang; Thomas N Chase
Kainic acid-induced apoptosis in rat striatum is associated with nuclear factor-kappaB activation.
Journal of neurochemistry 2000;74(2):647-58.
2000: Justin D Oh; K Chartisathian; Thomas N Chase; L L Butcher
Overexpression of neurotrophin receptor p75 contributes to the excitotoxin-induced cholinergic neuronal death in rat basal forebrain.
Brain research 2000;853(2):174-85.
2000: Leo Verhagen Metman; Spiros Konitsiotis; Thomas N Chase
Pathophysiology of motor response complications in Parkinson's disease: hypotheses on the why, where, and what.
Movement disorders : official journal of the Movement Disorder Society 2000;15(1):3-8.
1999: M Catherine Bennett; JF Bishop; Yan Leng; P B Chock; Thomas N Chase; M Maral Mouradian
Degradation of alpha-synuclein by proteasome.
The Journal of biological chemistry 1999;274(48):33855-8.
1999: Yves Agid; E Ahlskog; A Albanese; Donald B Calne; Thomas N Chase; J De Yebenes; Stewart A Factor; Stanley Fahn; Oscar S Gershanik; Christopher G Goetz; William Koller; M Kurth; Anthony E Lang; Andrew J Lees; Peter LeWitt; D Marsden; Eldad Melamed; Patrick P Michel; Yoshikuni Mizuno; Jose A Obeso; Wolfgang H Oertel; W Olanow; Werner Poewe; Pierre Pollak; Eduardo Tolosa
Levodopa in the treatment of Parkinson's disease: a consensus meeting.
Movement disorders : official journal of the Movement Disorder Society 1999;14(6):911-3.
1999: Leo Verhagen Metman; Paolo Del Dotto; K LePoole; Spiros Konitsiotis; J Fang; Thomas N Chase
Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study.
Archives of neurology 1999;56(11):1383-6.
1999: Pierre J Blanchet; Spiros Konitsiotis; Edward R Whittemore; Zhang-Lin Zhou; Richard M Woodward; Thomas N Chase
Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys.
The Journal of pharmacology and experimental therapeutics 1999;290(3):1034-40.
1999: Pierre J Blanchet; J Fang; Keith Hyland; Lauren A Arnold; M Maral Mouradian; Thomas N Chase
Short-term effects of high-dose 17beta-estradiol in postmenopausal PD patients: a crossover study.
Neurology 1999;53(1):91-5.
1999: Zheng-Hong Qin; Ren-Wu Chen; Yun Wang; M Nakai; De-Maw Chuang; Thomas N Chase
Nuclear factor kappaB nuclear translocation upregulates c-Myc and p53 expression during NMDA receptor-mediated apoptosis in rat striatum.
The Journal of neuroscience : the official journal of the Society for Neuroscience 1999;19(10):4023-33.
1999: Justin D Oh; C L Vaughan; Thomas N Chase
Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits.
Brain research 1999;821(2):433-42.
1999: M Nakai; Zheng-Hong Qin; Yumei Wang; Thomas N Chase
Free radical scavenger OPC-14117 attenuates quinolinic acid-induced NF-kappaB activation and apoptosis in rat striatum.
Brain research. Molecular brain research 1999;64(1):59-68.
1999: Yumei Wang; Zheng-Hong Qin; M Nakai; Ren-Wu Chen; De-Maw Chuang; Thomas N Chase
Co-stimulation of cyclic-AMP-linked metabotropic glutamate receptors in rat striatum attenuates excitotoxin-induced nuclear factor-kappaB activation and apoptosis.
Neuroscience 1999;94(4):1153-62.
1998: Justin D Oh; D S Russell; C L Vaughan; Thomas N Chase; D Russell
Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and L-DOPA administration.
Brain research 1998;813(1):150-9.
1998: Pierre J Blanchet; J Fang; M Gillespie; LuAnn A Sabounjian; K W Locke; Richard E Gammans; M Maral Mouradian; Thomas N Chase
Effects of the full dopamine D1 receptor agonist dihydrexidine in Parkinson's disease.
Clinical neuropharmacology 1998;21(6):339-43.
1998: Pierre J Blanchet; Spiros Konitsiotis; Keith Hyland; Lauren A Arnold; KD Pettigrew; Thomas N Chase
Chronic exposure to MPTP as a primate model of progressive parkinsonism: a pilot study with a free radical scavenger.
Experimental neurology 1998;153(2):214-22.
1998: Pierre J Blanchet; Spiros Konitsiotis; Thomas N Chase
Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys.
Movement disorders : official journal of the Movement Disorder Society 1998;13(5):798-802.
1998: Stanley Fahn; K E Clarence-Smith; Thomas N Chase
Parkinson's disease: neurodegenerative mechanisms and neuroprotective interventions--report of a workshop.
Movement disorders : official journal of the Movement Disorder Society 1998;13(5):759-67.
1998: Thomas N Chase; Justin D Oh; Pierre J Blanchet
Neostriatal mechanisms in Parkinson's disease.
Neurology 1998;51(2 Suppl 2):S30-5.
1998: L Verhagen Metman; Paolo Del Dotto; R Natté; Pepijn van den Munckhof; Thomas N Chase
Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease.
Neurology 1998;51(1):203-6.
1998: C Randolph; M C Tierney; E Mohr; Thomas N Chase
The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity.
Journal of clinical and experimental neuropsychology 1998;20(3):310-9.
1998: L Verhagen Metman; Pierre J Blanchet; Pepijn van den Munckhof; Paolo Del Dotto; R Natté; Thomas N Chase
A trial of dextromethorphan in parkinsonian patients with motor response complications.
Movement disorders : official journal of the Movement Disorder Society 1998;13(3):414-7.
1998: L Verhagen Metman; Paolo Del Dotto; Pepijn van den Munckhof; J Fang; M Maral Mouradian; Thomas N Chase
Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease.
Neurology 1998;50(5):1323-6.
1998: Thomas N Chase
Levodopa therapy: consequences of the nonphysiologic replacement of dopamine.
Neurology 1998;50(5 Suppl 5):S17-25.
1998: Yves Agid; Thomas N Chase; D Marsden
Adverse reactions to levodopa: drug toxicity or progression of disease?
Lancet 1998;351(9106):851-2.
1998: Pepijn van den Munckhof; Frederick A Lenz; Thomas N Chase
Square-wave action dystonia in Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 1998;13(2):354-6.
1998: L Verhagen Metman; Paolo Del Dotto; Pierre J Blanchet; Pepijn van den Munckhof; Thomas N Chase
Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease.
Amino acids 1998;14(1-3):75-82.
1998: Thomas N Chase
The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.
Drugs 1998;55 Suppl 1():1-9.
1998: Zheng-Hong Qin; Yumei Wang; M Nakai; Thomas N Chase
Nuclear factor-kappa B contributes to excitotoxin-induced apoptosis in rat striatum.
Molecular pharmacology 1998;53(1):33-42.
1997: Pierre J Blanchet; Spiros Konitsiotis; Thomas N Chase
Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
The Journal of pharmacology and experimental therapeutics 1997;283(2):794-9.
1997: Yumei Wang; Zheng-Hong Qin; M Nakai; Thomas N Chase
Glutamate metabotropic receptor agonist 1S,3R-ACPD induces internucleosomal DNA fragmentation and cell death in rat striatum.
Brain research 1997;772(1-2):45-56.
1997: Thomas N Chase
A gene for Parkinson disease.
Archives of neurology 1997;54(9):1156-7.
1997: Leo Verhagen Metman; Pepijn van den Munckhof; A A Klaassen; P Blanchet; M Maral Mouradian; Thomas N Chase
Effects of supra-threshold levodopa doses on dyskinesias in advanced Parkinson's disease.
Neurology 1997;49(3):711-3.
1997: Pierre J Blanchet; S M Papa; Leo Verhagen Metman; M Maral Mouradian; Thomas N Chase
Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease.
Neuroscience and biobehavioral reviews 1997;21(4):447-53.
1997: M M Mouradian; Thomas N Chase
Gene therapy for Parkinson's disease: current knowledge and future perspective.
Gene therapy 1997;4(6):504-6.
1997: Justin D Oh; Paolo Del Dotto; Thomas N Chase
Protein kinase A inhibitor attenuates levodopa-induced motor response alterations in the hemi-parkinsonian rat.
Neuroscience letters 1997;228(1):5-8.
1997: M Maral Mouradian; Thomas N Chase
Gene therapy for Parkinson's disease: an approach to the prevention or palliation of levodopa-associated motor complications.
Experimental neurology 1997;144(1):51-7.
1997: Kiyomitsu Oyanagi; T Makifuchi; T Ohtoh; K M Chen; D Carleton Gajdusek; Thomas N Chase
Distinct pathological features of the gallyas- and tau-positive glia in the Parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam.
Journal of neuropathology and experimental neurology 1997;56(3):308-16.
1997: L Verhagen Metman; E R Locatelli; D Bravi; M Maral Mouradian; Thomas N Chase
Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications.
Neurology 1997;48(2):369-72.
1996: C Marin; S Papa; T M Engber; M Bonastre; E Tolosa; Thomas N Chase
MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats.
Brain research 1996;736(1-2):202-5.
1996: R Blesa; E Mohr; R S Miletich; K Hildebrand; Sampson Margaret; Thomas N Chase
Cerebral metabolic changes in Alzheimer's disease: neurobehavioral patterns.
Dementia (Basel, Switzerland) 1996;7(5):239-45.
1996: Pierre J Blanchet; Leo Verhagen Metman; M Maral Mouradian; Thomas N Chase
Acute pharmacologic blockade of dyskinesias in Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 1996;11(5):580-1.
1996: Gioacchino Tedeschi; Alessandro Bertolino; NM Lundbom; Simona Bonavita; Nicholas Patronas; Jeff H Duyn; Leo Verhagen Metman; Thomas N Chase; G Di Chiro
Cortical and subcortical chemical pathology in Alzheimer's disease as assessed by multislice proton magnetic resonance spectroscopic imaging.
Neurology 1996;47(3):696-704.
1996: C Marin; T M Engber; M Bonastre; Thomas N Chase; E Tolosa
Effect of long-term haloperidol treatment on striatal neuropeptides: relation to stereotyped behavior.
Brain research 1996;731(1-2):57-62.
1996: Zheng-Hong Qin; Yumei Wang; Thomas N Chase
Stimulation of N-methyl-D-aspartate receptors induces apoptosis in rat brain.
Brain research 1996;725(2):166-76.
1996: Leo Verhagen Metman; Pierre J Blanchet; D de Jong; M Maral Mouradian; Thomas N Chase
Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 1996;11(3):257-60.
1996: S M Papa; Thomas N Chase
Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys.
Annals of neurology 1996;39(5):574-8.
1996: J J Anderson; A M Kask; Thomas N Chase
Effects of cannabinoid receptor stimulation and blockade on catalepsy produced by dopamine receptor antagonists.
European journal of pharmacology 1996;295(2-3):163-8.
1996: C Marin; T M Engber; P Chaudhuri; A Peppe; Thomas N Chase
Effects of kappa receptor agonists on D1 and D2 dopamine agonist and antagonist-induced behaviors.
Psychopharmacology 1996;123(2):215-21.
1996: Thomas N Chase; T M Engber; M Maral Mouradian
Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease.
Advances in neurology 1996;69():497-501.
1995: S M Papa; R C Boldry; T M Engber; A M Kask; Thomas N Chase
Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade.
Brain research 1995;701(1-2):13-8.
1995: Allen R Braun; C Randolph; B Stoetter; E Mohr; Christiane Sylvia Cox; K Vladar; R Sexton; Richard E Carson; Peter Herscovitch; Thomas N Chase
The functional neuroanatomy of Tourette's syndrome: an FDG-PET Study. II: Relationships between regional cerebral metabolism and associated behavioral and cognitive features of the illness.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1995;13(2):151-68.
1995: R Blesa; E Mohr; R S Miletich; Thomas N Chase
Limbic system dysfunction in Alzheimer's disease.
Journal of neurology, neurosurgery, and psychiatry 1995;59(4):450-1.
1995: R C Boldry; S M Papa; A M Kask; Thomas N Chase
MK-801 reverses effects of chronic levodopa on D1 and D2 dopamine agonist-induced rotational behavior.
Brain research 1995;692(1-2):259-64.
1995: L A Anderson; J J Anderson; Thomas N Chase; Judith R Walters
The cannabinoid agonists WIN 55,212-2 and CP 55,940 attenuate rotational behavior induced by a dopamine D1 but not a D2 agonist in rats with unilateral lesions of the nigrostriatal pathway.
Brain research 1995;691(1-2):106-14.
1995: J J Anderson; S Randall; Thomas N Chase
The neurokinin1 receptor antagonist CP-99,994 reduces catalepsy produced by the dopamine D2 receptor antagonist raclopride: correlation with extracellular acetylcholine levels in striatum.
The Journal of pharmacology and experimental therapeutics 1995;274(2):928-36.
1995: Thomas N Chase; Carol A Tamminga
Alzheimer's dementia.
The American journal of psychiatry 1995;152(8):1110.
1995: C Marin; Thomas N Chase
Effects of SCH 32615, an enkephalinase inhibitor, on D-1 and D-2 dopamine receptor-mediated behaviors.
Neuropharmacology 1995;34(6):677-82.
1995: C Randolph; M C Tierney; Thomas N Chase
Implicit memory in Alzheimer's disease.
Journal of clinical and experimental neuropsychology 1995;17(3):343-51.
1994: T M Engber; S M Papa; R C Boldry; Thomas N Chase
NMDA receptor blockade reverses motor response alterations induced by levodopa.
Neuroreport 1994;5(18):2586-8.
1994: K Oyanagi; T Makifuchi; T Ohtoh; F Ikuta; K M Chen; Thomas N Chase; D Carleton Gajdusek
Topographic investigation of brain atrophy in parkinsonism-dementia complex of Guam: a comparison with Alzheimer's disease and progressive supranuclear palsy.
Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration 1994;3(4):301-4.
1994: S M Papa; T M Engber; A M Kask; Thomas N Chase
Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration.
Brain research 1994;662(1-2):69-74.
1994: Leo Verhagen Metman; V H Sethy; J R Roberts; D Bravi; J I Hoff; M Maral Mouradian; Thomas N Chase
Motor effects of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 1994;9(5):577-81.
1994: J J Anderson; S Kuo; Thomas N Chase
Endogenous excitatory amino acids tonically stimulate striatal acetylcholine release through NMDA but not AMPA receptors.
Neuroscience letters 1994;176(2):264-8.
1994: I Litvan; R Blesa; K Clark; Paolo Nichelli; J R Atack; M Maral Mouradian; Jordan Grafman; Thomas N Chase
Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy.
Annals of neurology 1994;36(1):55-61.
1994: D Bravi; M Maral Mouradian; J W Roberts; T L Davis; Y H Sohn; Thomas N Chase
Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms.
Annals of neurology 1994;36(1):27-31.
1994: Leo Verhagen Metman; J Hoff; M Maral Mouradian; Thomas N Chase
Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa.
Movement disorders : official journal of the Movement Disorder Society 1994;9(4):463-5.
1994: Thomas N Chase; T M Engber; M Maral Mouradian
Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease.
Neurology 1994;44(7 Suppl 6):S15-8.
1994: J J Anderson; S Kuo; Thomas N Chase; T M Engber
Dopamine D1 receptor-stimulated release of acetylcholine in rat striatum is mediated indirectly by activation of striatal neurokinin1 receptors.
The Journal of pharmacology and experimental therapeutics 1994;269(3):1144-51.
1994: J Blin; Monford Piercey; M E Giuffra; M Maral Mouradian; Thomas N Chase
Metabolic effects of scopolamine and physostigmine in human brain measured by positron emission tomography.
Journal of the neurological sciences 1994;123(1-2):44-51.
1994: Y H Sohn; Leo Verhagen Metman; D Bravi; I Linfante; A Aotsuka; M Maral Mouradian; Thomas N Chase
Levodopa peak response time reflects severity of dopamine neuron loss in Parkinson's disease.
Neurology 1994;44(4):755-7.
1994: T M Engber; J J Anderson; R C Boldry; S M Papa; S Kuo; Thomas N Chase
Excitatory amino acid receptor antagonists modify regional cerebral metabolic responses to levodopa in 6-hydroxydopamine-lesioned rats.
Neuroscience 1994;59(2):389-99.
1994: J Blin; C A Ray; Monford Piercey; J J Bartko; M Maral Mouradian; Thomas N Chase
Comparison of cholinergic drug effects on regional brain glucose consumption in rats and humans by means of autoradiography and position emission tomography.
Brain research 1994;635(1-2):196-202.
1994: C Randolph; J W Roberts; M C Tierney; D Bravi; M Maral Mouradian; Thomas N Chase
D-cycloserine treatment of Alzheimer disease.
Alzheimer disease and associated disorders 1994;8(3):198-205.
1994: K Oyanagi; T Makifuchi; T Ohtoh; K M Chen; D Carleton Gajdusek; Thomas N Chase; F Ikuta
The neostriatum and nucleus accumbens in parkinsonism-dementia complex of Guam: a pathological comparison with Alzheimer's disease and progressive supranuclear palsy.
Acta neuropathologica 1994;88(2):122-8.
1994: K Oyanagi; T Makifuchi; T Ohtoh; K M Chen; T van der Schaaf; D Carleton Gajdusek; Thomas N Chase; F Ikuta
Amyotrophic lateral sclerosis of Guam: the nature of the neuropathological findings.
Acta neuropathologica 1994;88(5):405-12.
1993: Allen R Braun; B Stoetter; C Randolph; J K Hsiao; K Vladar; J Gernert; Richard E Carson; Peter Herscovitch; Thomas N Chase
The functional neuroanatomy of Tourette's syndrome: an FDG-PET study. I. Regional changes in cerebral glucose metabolism differentiating patients and controls.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1993;9(4):277-91.
1993: Thomas N Chase; M Maral Mouradian; T M Engber
Motor response complications and the function of striatal efferent systems.
Neurology 1993;43(12 Suppl 6):S23-7.
1993: J W Roberts; G Cora-Locatelli; D Bravi; M A Amantea; M Maral Mouradian; Thomas N Chase
Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients.
Neurology 1993;43(12):2685-8.
1993: R C Boldry; Thomas N Chase; T M Engber
Influence of previous exposure to levodopa on the interaction between dizocilpine and dopamine D1 and D2 agonists in rats with 6-hydroxydopamine-induced lesions.
The Journal of pharmacology and experimental therapeutics 1993;267(3):1454-9.
1993: D Bravi; M Maral Mouradian; J W Roberts; T L Davis; Thomas N Chase
End-of-dose dystonia in Parkinson's disease.
Neurology 1993;43(10):2130-1.
1993: J J Anderson; S Kuo; Thomas N Chase; T M Engber
GABAA and GABAB receptors differentially regulate striatal acetylcholine release in vivo.
Neuroscience letters 1993;160(2):126-30.
1993: M Giuffra; M Maral Mouradian; T L Davis; J Ownby; Thomas N Chase
Dynorphin agonist therapy of Parkinson's disease.
Clinical neuropharmacology 1993;16(5):444-7.
1993: J J Anderson; Thomas N Chase; T M Engber
Substance P increases release of acetylcholine in the dorsal striatum of freely moving rats.
Brain research 1993;623(2):189-94.
1993: C Randolph; E Mohr; Thomas N Chase
Assessment of intellectual function in dementing disorders: validity of WAIS-R short forms for patients with Alzheimer's, Huntington's, and Parkinson's disease.
Journal of clinical and experimental neuropsychology 1993;15(5):743-53.
1993: J W Roberts; J M Hoeg; M M Mouradian; I Linfante; Thomas N Chase
Iatrogenic hyperlipidaemia with GM1 ganglioside.
Lancet 1993;342(8863):115.
1993: T M Engber; C Marin; Z Susel; Thomas N Chase
Differential effects of chronic dopamine D1 and D2 receptor agonists on rotational behavior and dopamine receptor binding.
European journal of pharmacology 1993;236(3):385-93.
1993: T M Engber; J J Anderson; R C Boldry; S Kuo; Thomas N Chase
N-methyl-D-aspartate receptor blockade differentially modifies regional cerebral metabolic responses to D1 and D2 dopamine agonists in rats with a unilateral 6-hydroxydopamine lesion.
Neuroscience 1993;54(4):1051-61.
1993: C Marin; S A Parashos; V Kapitzoglou-Logothetis; A Peppe; Thomas N Chase
D1 and D2 dopamine receptor-mediated mechanisms and behavioral supersensitivity.
Pharmacology, biochemistry, and behavior 1993;45(1):195-200.
1993: J J Anderson; D Bravi; R Ferrari; T L Davis; fabio baronti; Thomas N Chase; F Dagani
No evidence for altered muscle mitochondrial function in Parkinson's disease.
Journal of neurology, neurosurgery, and psychiatry 1993;56(5):477-80.
1993: D A Jauch; V H Sethy; B G Weick; Thomas N Chase; Robert Schwarcz
Intravenous administration of L-kynurenine to rhesus monkeys: effect on quinolinate and kynurenate levels in serum and cerebrospinal fluid.
Neuropharmacology 1993;32(5):467-72.
1993: D Bravi; T L Davis; M Maral Mouradian; Thomas N Chase
Treatment of Parkinson's disease with the partial dopamine agonist EMD 49980.
Movement disorders : official journal of the Movement Disorder Society 1993;8(2):195-7.
1993: S M Papa; T M Engber; R C Boldry; Thomas N Chase
Opposite effects of NMDA and AMPA receptor blockade on catalepsy induced by dopamine receptor antagonists.
European journal of pharmacology 1993;232(2-3):247-53.
1993: C Marin; Thomas N Chase
Dopamine D1 receptor stimulation but not dopamine D2 receptor stimulation attenuates haloperidol-induced behavioral supersensitivity and receptor up-regulation.
European journal of pharmacology 1993;231(2):191-6.
1993: R C Boldry; M D Kelland; T M Engber; Thomas N Chase
NBQX inhibits AMPA-induced locomotion after injection into the nucleus accumbens.
Brain research 1993;600(2):331-4.
1993: A Peppe; J M Dambrosia; Thomas N Chase
Risk factors for motor response complications in L-dopa-treated parkinsonian patients.
Advances in neurology 1993;60():698-702.
1993: Thomas N Chase; T M Engber; M Maral Mouradian
Striatal dopaminoceptive system changes and motor response complications in L-dopa-treated patients with advanced Parkinson's disease.
Advances in neurology 1993;60():181-5.
1993: M E Giuffra; V H Sethy; T L Davis; M Maral Mouradian; Thomas N Chase
Milacemide therapy for Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 1993;8(1):47-50.
1992: fabio baronti; M Maral Mouradian; T L Davis; M Giuffra; G Brughitta; Katherine Conant; Thomas N Chase
Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease.
Annals of neurology 1992;32(6):776-81.
1992: C A Ray; J Blin; Thomas N Chase; Monford Piercey
Effects of cholinergic agonists on regional brain energy metabolism in the scopolamine-treated rat.
Neuropharmacology 1992;31(11):1193-9.
1992: U M Mann; E Mohr; M Gearing; Thomas N Chase
Heterogeneity in Alzheimer's disease: progression rate segregated by distinct neuropsychological and cerebral metabolic profiles.
Journal of neurology, neurosurgery, and psychiatry 1992;55(10):956-9.
1992: J J Anderson; Thomas N Chase; T M Engber
Differential effect of subthalamic nucleus ablation on dopamine D1 and D2 agonist-induced rotation in 6-hydroxydopamine-lesioned rats.
Brain research 1992;588(2):307-10.
1992: F Dagani; J J Anderson; Thomas N Chase
Mitochondrial function in Parkinson's disease.
Annals of neurology 1992;32(2):226-7.
1992: I Litvan; W H Berrettini; J R Atack; Thomas N Chase
CSF galanin and neuropeptide Y immunoreactivity in progressive supranuclear palsy.
Acta neurologica Scandinavica 1992;86(2):204-6.
1992: Carol A Tamminga; Gunvant K Thaker; Robert W Buchanan; Brian Kirkpatrick; L D Alphs; Thomas N Chase; William T Carpenter
Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome.
Archives of general psychiatry 1992;49(7):522-30.
1992: fabio baronti; M Maral Mouradian; Katherine Conant; M Giuffra; G Brughitta; Thomas N Chase
Partial dopamine agonist therapy of levodopa-induced dyskinesias.
Neurology 1992;42(6):1241-3.
1992: T M Engber; R C Boldry; S Kuo; Thomas N Chase
Dopaminergic modulation of striatal neuropeptides: differential effects of D1 and D2 receptor stimulation on somatostatin, neuropeptide Y, neurotensin, dynorphin and enkephalin.
Brain research 1992;581(2):261-8.
1992: E Mohr; U M Mann; R S Miletich; Sampson Margaret; Terry Goldberg; J D Grimes; Thomas N Chase
Neuropsychological and glucose metabolic profiles in asymmetric Parkinson's disease.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 1992;19(2):163-9.
1992: M E Giuffra; M Maral Mouradian; Thomas N Chase
Glutamatergic therapy of Huntington's chorea.
Clinical neuropharmacology 1992;15(2):148-51.
1992: fabio baronti; T L Davis; R C Boldry; M Maral Mouradian; Thomas N Chase
Deprenyl effects on levodopa pharmacodynamics, mood, and free radical scavenging.
Neurology 1992;42(3 Pt 1):541-4.
1992: I J Heuser; fabio baronti; C A Marin; N Ma; G R Merriam; Thomas N Chase; M Maral Mouradian
Growth hormone secretion in Alzheimer's disease: 24-hour profile of basal levels and response to stimulation and suppression studies.
Neurobiology of aging 1992;13(2):255-60.
1992: T M Engber; Z Susel; B G Weick; Judith R Walters; Thomas N Chase
Effects of chronic levodopa on D1 and D2 receptor-mediated striatal output.
Neurochemistry international 1992;20 Suppl():255S-260S.
1992: D Naber; Daniel R Weinberger; M Gillespie; Thomas N Chase
Failure of buspirone and verapamil to improve spasmodic torticollis.
The Journal of neuropsychiatry and clinical neurosciences 1992;4(1):82-4.
1992: D Bravi; J J Anderson; F Dagani; T L Davis; R Ferrari; M Gillespie; Thomas N Chase
Effect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 1992;7(3):228-31.
1992: Daniel R Weinberger; D Jones; R C Reba; U Mann; Richard Coppola; R Gibson; Julia G Gorey; A Braun; Thomas N Chase
A comparison of FDG PET and IQNB SPECT in normal subjects and in patients with dementia.
The Journal of neuropsychiatry and clinical neurosciences 1992;4(3):239-48.
1992: D J Cohen; A J Friedhoff; James F Leckman; Thomas N Chase
Tourette syndrome. Extending basic research to clinical care.
Advances in neurology 1992;58():341-62.
1992: B Stoetter; Allen R Braun; C Randolph; J Gernert; Richard E Carson; Peter Herscovitch; Thomas N Chase
Functional neuroanatomy of Tourette syndrome. Limbic-motor interactions studied with FDG PET.
Advances in neurology 1992;58():213-26.
1991: J Blin; C A Ray; Thomas N Chase; Monford Piercey
Regional cerebral glucose metabolism compared in rodents and humans.
Brain research 1991;568(1-2):215-22.
1991: fabio baronti; Stefano Ruggieri; M Maral Mouradian; A Bonamartini; P Bocciarelli; Maria Francesca De Pandis; Thomas N Chase; A Agnoli
[Changes in the nigrostriatal dopamine receptor compartment after continuous dopaminergic infusions in Parkinson disease].
Rivista di neurologia 1991;61(6):210-4.
1991: I J Heuser; Thomas N Chase; M Maral Mouradian
The limbic-hypothalamic-pituitary-adrenal axis in Huntington's disease.
Biological psychiatry 1991;30(9):943-52.
1991: M Maral Mouradian; J Blin; M Giuffra; I J Heuser; fabio baronti; J Ownby; Thomas N Chase
Somatostatin replacement therapy for Alzheimer dementia.
Annals of neurology 1991;30(4):610-3.
1991: fabio baronti; Katherine Conant; M Giuffra; T L Davis; G Brughitta; Michael Iadarola; W H Berrettini; Thomas N Chase; M Maral Mouradian
Opioid peptides in Parkinson's disease: effects of dopamine repletion.
Brain research 1991;560(1-2):92-6.
1991: J R Atack; I Litvan; Leon J Thal; Conrad May; Stanley I Rapoport; Thomas N Chase
Cerebrospinal fluid acetylcholinesterase in progressive supranuclear palsy: reduced activity relative to normal subjects and lack of inhibition by oral physostigmine.
Journal of neurology, neurosurgery, and psychiatry 1991;54(9):832-5.
1991: T M Engber; R C Boldry; Thomas N Chase
The kappa-opioid receptor agonist spiradoline differentially alters the rotational response to dopamine D1 and D2 agonists.
European journal of pharmacology 1991;200(1):171-3.
1991: T M Engber; Z Susel; S Kuo; Charles R Gerfen; Thomas N Chase
Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats.
Brain research 1991;552(1):113-8.
1991: M Maral Mouradian; I J Heuser; fabio baronti; M Giuffra; Katherine Conant; T L Davis; Thomas N Chase
Comparison of the clinical pharmacology of (-)NPA and levodopa in Parkinson's disease.
Journal of neurology, neurosurgery, and psychiatry 1991;54(5):401-5.
1991: J J Claus; C Ludwig; E Mohr; M Giuffra; J Blin; Thomas N Chase
Nootropic drugs in Alzheimer's disease: symptomatic treatment with pramiracetam.
Neurology 1991;41(4):570-4.
1991: M A Ariano; T M Engber; Z Susel; Thomas N Chase
Striatal D1 dopamine receptor morphochemistry following continuous or intermittent L-dopa replacement therapy.
Experimental neurology 1991;112(1):112-8.
1991: C Marin; S A Parashos; Thomas N Chase
Effect of Gi protein ADP-ribosylation induced by pertussis toxin on dopamine-mediated behaviors.
European journal of pharmacology 1991;195(1):19-25.
1991: J J Claus; E Mohr; Thomas N Chase
Clinical trials in dementia: learning effects with repeated testing.
Journal of psychiatry & neuroscience : JPN 1991;16(1):1-4.
1991: Z Susel; T M Engber; S Kuo; Thomas N Chase
Prolonged infusion of quinolinic acid into rat striatum as an excitotoxic model of neurodegenerative disease.
Neuroscience letters 1991;121(1-2):234-8.
1991: I Litvan; E Mohr; J Williams; C Gomez; Thomas N Chase
Differential memory and executive functions in demented patients with Parkinson's and Alzheimer's disease.
Journal of neurology, neurosurgery, and psychiatry 1991;54(1):25-9.
1991: E Mohr; Pim Brouwers; J J Claus; U M Mann; P Fedio; Thomas N Chase
Visuospatial cognition in Huntington's disease.
Movement disorders : official journal of the Movement Disorder Society 1991;6(2):127-32.
1991: F Dagani; R Ferrari; J J Anderson; Thomas N Chase
L-dopa does not affect electron transfer chain enzymes and respiration of rat muscle mitochondria.
Movement disorders : official journal of the Movement Disorder Society 1991;6(4):315-9.
1990: Charles R Gerfen; T M Engber; L C Mahan; Z Susel; Thomas N Chase; F J Monsma; David R Sibley
D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons.
Science (New York, N.Y.) 1990;250(4986):1429-32.
1990: T M Engber; Z Susel; S Kuo; Thomas N Chase
Chronic levodopa treatment alters basal and dopamine agonist-stimulated cerebral glucose utilization.
The Journal of neuroscience : the official journal of the Society for Neuroscience 1990;10(12):3889-95.
1990: E Mohr; U M Mann; Thomas N Chase
Subgroups in Alzheimer's disease: fact or fiction?
Psychiatric journal of the University of Ottawa : Revue de psychiatrie de l'Université d'Ottawa 1990;15(4):203-6.
1990: E Mohr; I Litvan; J Williams; P Fedio; Thomas N Chase
Selective deficits in Alzheimer and parkinsonian dementia: visuospatial function.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 1990;17(3):292-7.
1990: B G Weick; T M Engber; Z Susel; Thomas N Chase; Judith R Walters
Responses of substantia nigra pars reticulata neurons to GABA and SKF 38393 in 6-hydroxydopamine-lesioned rats are differentially affected by continuous and intermittent levodopa administration.
Brain research 1990;523(1):16-22.
1990: E Mohr; Jorge L Juncos; Christiane Sylvia Cox; I Litvan; P Fedio; Thomas N Chase
Selective deficits in cognition and memory in high-functioning parkinsonian patients.
Journal of neurology, neurosurgery, and psychiatry 1990;53(7):603-6.
1990: Jordan Grafman; I Litvan; C Gomez; Thomas N Chase
Frontal lobe function in progressive supranuclear palsy.
Archives of neurology 1990;47(5):553-8.
1990: E Mohr; Christiane Sylvia Cox; J Williams; Thomas N Chase; P Fedio
Impairment of central auditory function in Alzheimer's disease.
Journal of clinical and experimental neuropsychology 1990;12(2):235-46.
1990: M Maral Mouradian; I J Heuser; fabio baronti; Thomas N Chase
Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease.
Annals of neurology 1990;27(1):18-23.
1990: H S Pan; T M Engber; Thomas N Chase; Judith R Walters
The effects of striatal lesion on turning behavior and globus pallidus single unit response to dopamine agonist administration.
Life sciences 1990;46(1):73-80.
1990: Daniel R Weinberger; U Mann; R E Gibson; Richard Coppola; D W Jones; Allen R Braun; K F Berman; Trey Sunderland; R C Reba; Thomas N Chase
Cerebral muscarinic receptors in primary degenerative dementia as evaluated by SPECT with iodine-123-labeled QNB.
Advances in neurology 1990;51():147-50.
1990: S A Parashos; C Marin; P Barone; V Kapitzoglou-Logothetis; Thomas N Chase
Effect of chronic D-1 and/or D-2 dopamine antagonist treatment on SKF 38393-induced non-stereotyped grooming.
Psychopharmacology 1990;102(3):411-3.
1990: Thomas N Chase; Giovanni Fabbrini; Jorge L Juncos; M Maral Mouradian
Motor response complications with chronic levodopa therapy.
Advances in neurology 1990;53():377-81.
1990: P Barone; S A Parashos; V Palma; C Marin; G Campanella; Thomas N Chase
Dopamine D1 receptor modulation of pilocarpine-induced convulsions.
Neuroscience 1990;34(1):209-17.
1989: Thomas N Chase; fabio baronti; Giovanni Fabbrini; I J Heuser; Jorge L Juncos; M Maral Mouradian
Rationale for continuous dopaminomimetic therapy of Parkinson's disease.
Neurology 1989;39(11 Suppl 2):7-10; discussion 19.
1989: M M Mourdian; Melvyn P Heyes; J B Pan; I J Heuser; Sanford Markey; Thomas N Chase; M M Mouradian
No changes in central quinolinic acid levels in Alzheimer's disease.
Neuroscience letters 1989;105(1-2):233-8.
1989: S A Parashos; C Marin; Thomas N Chase
Synergy between a selective D1 antagonist and a selective D2 antagonist in the induction of catalepsy.
Neuroscience letters 1989;105(1-2):169-73.
1989: U M Mann; E Mohr; Thomas N Chase
Rapidly progressive Alzheimer's disease.
Lancet 1989;2(8666):799.
1989: Z Susel; T M Engber; Thomas N Chase
Behavioral evaluation of the anti-excitotoxic properties of MK-801: comparison with neurochemical measurements.
Neuroscience letters 1989;104(1-2):125-9.
1989: T M Engber; Z Susel; Jorge L Juncos; Thomas N Chase
Continuous and intermittent levodopa differentially affect rotation induced by D-1 and D-2 dopamine agonists.
European journal of pharmacology 1989;168(3):291-8.
1989: I Litvan; C Gomez; J R Atack; M Gillespie; A M Kask; M Maral Mouradian; Thomas N Chase
Physostigmine treatment of progressive supranuclear palsy.
Annals of neurology 1989;26(3):404-7.
1989: I Litvan; Jordan Grafman; C Gomez; Thomas N Chase
Memory impairment in patients with progressive supranuclear palsy.
Archives of neurology 1989;46(7):765-7.
1989: M Maral Mouradian; I J Heuser; fabio baronti; Giovanni Fabbrini; Jorge L Juncos; Thomas N Chase
Pathogenesis of dyskinesias in Parkinson's disease.
Annals of neurology 1989;25(5):523-6.
1989: Jorge L Juncos; T M Engber; R Raisman; Z Susel; Florence Thibaut; A Ploska; Yves Agid; Thomas N Chase
Continuous and intermittent levodopa differentially affect basal ganglia function.
Annals of neurology 1989;25(5):473-8.
1989: A Braun; M Maral Mouradian; E Mohr; Giovanni Fabbrini; Thomas N Chase
Selective D-1 dopamine receptor agonist effects in hyperkinetic extrapyramidal disorders.
Journal of neurology, neurosurgery, and psychiatry 1989;52(5):631-5.
1989: E Mohr; J Schlegel; G Fabbrini; J Williams; M M Mouradian; U M Mann; J J Claus; P Fedio; Thomas N Chase
Clonidine treatment of Alzheimer's disease.
Archives of neurology 1989;46(4):376-8.
1989: P Barone; V Palma; S A Parashos; C Marin; Thomas N Chase; G Campanella
D-1 dopamine agonist administration reduces the threshold for convulsions produced by pilocarpine.
Bollettino della Società italiana di biologia sperimentale 1989;65(4):337-41.
1989: J Schlegel; E Mohr; J Williams; U Mann; M Gearing; Thomas N Chase
Guanfacine treatment of Alzheimer's disease.
Clinical neuropharmacology 1989;12(2):124-8.
1989: S A Parashos; P Barone; C A Marin; A J Paraschos; V Kapitzoglou-Logothetis; Thomas N Chase
Haloperidol- and SCH23390-induced dopaminergic supersensitivities are not additive in the rat.
Psychopharmacology 1989;98(2):189-92.
1989: E Mohr; G Fabbrini; J Williams; J Schlegel; Christiane Sylvia Cox; P Fedio; Thomas N Chase
Dopamine and memory function in Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society 1989;4(2):113-20.
1988: T M Engber; Thomas N Chase
Dextromethorphan does not protect against quinolinic acid neurotoxicity in rat striatum.
Neuroscience letters 1988;95(1-3):269-74.
1988: M M Mouradian; P C Contreras; J B Monahan; Thomas N Chase
[3H]MK-801 binding in Alzheimer's disease.
Neuroscience letters 1988;93(2-3):225-30.
1988: Thomas N Chase; Jorge L Juncos; Giovanni Fabbrini; M Maral Mouradian
Motor response complications in advanced Parkinson's disease.
Functional neurology 1988;3(4):429-36.
1988: M Maral Mouradian; Jorge L Juncos; Giovanni Fabbrini; J Schlegel; J J Bartko; Thomas N Chase
Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II.
Annals of neurology 1988;24(3):372-8.
1988: Giovanni Fabbrini; M Maral Mouradian; Jorge L Juncos; J Schlegel; E Mohr; Thomas N Chase
Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I.
Annals of neurology 1988;24(3):366-71.
1988: M Maral Mouradian; Thomas N Chase
Central mechanisms and levodopa response fluctuations in Parkinson's disease.
Clinical neuropharmacology 1988;11(4):378-85.
1988: Ted M Dawson; P Barone; A Sidhu; J K Wamsley; Thomas N Chase
The D1 dopamine receptor in the rat brain: quantitative autoradiographic localization using an iodinated ligand.
Neuroscience 1988;26(1):83-100.
1988: T Agui; Thomas N Chase; J W Kebabian
Identification of D1-dopamine receptor in chicken embryo retina with [125I]SCH 23982.
Brain research 1988;452(1-2):49-56.
1988: P Barone; I Tucci; S A Parashos; Thomas N Chase
Supersensitivity to a D-1 dopamine receptor agonist and subsensitivity to a D-2 receptor agonist following chronic D-1 receptor blockade.
European journal of pharmacology 1988;149(3):225-32.
1988: P H Sheridan; S Sato; N Foster; G Bruno; Christiane Sylvia Cox; P Fedio; Thomas N Chase
Relation of EEG alpha background to parietal lobe function in Alzheimer's disease as measured by positron emission tomography and psychometry.
Neurology 1988;38(5):747-50.
1988: M Maral Mouradian; E Mohr; J A Williams; Thomas N Chase
No response to high-dose muscarinic agonist therapy in Alzheimer's disease.
Neurology 1988;38(4):606-8.
1988: Allen R Braun; Thomas N Chase
Behavioral effects of chronic exposure to selective D-1 and D-2 dopamine receptor agonists.
European journal of pharmacology 1988;147(3):441-51.
1988: D Naber; Daniel R Weinberger; M Bullinger; M Polsby; Thomas N Chase
Personality variables, neurological and psychopathological symptoms in patients suffering from spasmodic torticollis.
Comprehensive psychiatry 1988;29(2):182-7.
1988: S L Pullman; Ray L Watts; Jorge L Juncos; Thomas N Chase; J N Sanes
Dopaminergic effects on simple and choice reaction time performance in Parkinson's disease.
Neurology 1988;38(2):249-54.
1988: Thomas N Chase; Carol A Tamminga; H Burrows
Positron emission tomographic studies of regional cerebral glucose metabolism in idiopathic dystonia.
Advances in neurology 1988;50():237-41.
1988: Thomas N Chase; M M Mouradian; Giovanni Fabbrini; Jorge L Juncos
Pathogenetic studies of motor fluctuations in Parkinson's disease.
Journal of neural transmission. Supplementum 1988;27():3-10.
1988: Daniel R Weinberger; Karen Faith Berman; Thomas N Chase
Mesocortical dopaminergic function and human cognition.
Annals of the New York Academy of Sciences 1988;537():330-8.
1988: Giovanni Fabbrini; A Braun; M Maral Mouradian; Carol A Tamminga; Thomas N Chase
Dopamine D-1 receptor agonist stimulation of prolactin secretion in man.
Journal of neural transmission 1988;71(3):159-63.
1988: Carol A Tamminga; G H Burrows; Thomas N Chase; L D Alphs; Gunvant K Thaker
Dopamine neuronal tracts in schizophrenia: their pharmacology and in vivo glucose metabolism.
Annals of the New York Academy of Sciences 1988;537():443-50.
1987: K Tanimoto; Carol A Tamminga; Thomas N Chase
Elevation of plasma prolactin concentrations by intravenous SCH 23390 and SKF 38393 in conscious rats.
European journal of pharmacology 1987;144(2):147-51.
1987: S A Parashos; P Barone; I Tucci; Thomas N Chase
Attenuation of D-1 antagonist-induced D-1 receptor upregulation by concomitant D-2 receptor blockade.
Life sciences 1987;41(20):2279-84.
1987: Jorge L Juncos; Giovanni Fabbrini; M M Mouradian; Thomas N Chase
Controlled release levodopa-carbidopa (CR-5) in the management of parkinsonian motor fluctuations.
Archives of neurology 1987;44(10):1010-2.
1987: Jorge L Juncos; Giovanni Fabbrini; M Maral Mouradian; C Serrati; Thomas N Chase
Dietary influences on the antiparkinsonian response to levodopa.
Archives of neurology 1987;44(10):1003-5.
1987: M Maral Mouradian; Jorge L Juncos; Giovanni Fabbrini; Thomas N Chase
Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies.
Annals of neurology 1987;22(4):475-9.
1987: P Barone; Krystof Bankiewicz; G U Corsini; irwin kopin; Thomas N Chase
Dopaminergic mechanisms in hemiparkinsonian monkeys.
Neurology 1987;37(10):1592-5.
1987: E Mohr; G Fabbrini; S Ruggieri; P Fedio; Thomas N Chase
Cognitive concomitants of dopamine system stimulation in parkinsonian patients.
Journal of neurology, neurosurgery, and psychiatry 1987;50(9):1192-6.
1987: Thomas N Chase; G H Burrows; E Mohr
Cortical glucose utilization patterns in primary degenerative dementias of the anterior and posterior type.
Archives of gerontology and geriatrics 1987;6(3):289-97.
1987: M Maral Mouradian; Jorge L Juncos; C Serrati; Giovanni Fabbrini; S Palmeri; Thomas N Chase
Exercise and the antiparkinsonian response to levodopa.
Clinical neuropharmacology 1987;10(4):351-5.
1987: Carol A Tamminga; K Tanimoto; S Kuo; M Beck; Thomas N Chase
Central cholecystokinin octapeptide reduces glucose utilization in subcortical but not cortical rat brain.
European journal of pharmacology 1987;139(2):237-41.
1987: Jorge L Juncos; M Maral Mouradian; Giovanni Fabbrini; C Serrati; Thomas N Chase
Levodopa methyl ester treatment of Parkinson's disease.
Neurology 1987;37(7):1242-5.
1987: K Tanimoto; Carol A Tamminga; Thomas N Chase; G Nilaver
Intracerebroventricular injection of cholecystokinin octapeptide elevates plasma prolactin levels through stimulation of vasoactive intestinal polypeptide.
Endocrinology 1987;121(1):127-32.
1987: P Barone; I Tucci; S A Parashos; Thomas N Chase
D-1 dopamine receptor changes after striatal quinolinic acid lesion.
European journal of pharmacology 1987;138(1):141-5.
1987: Judith R Walters; Debra A Bergstrom; J H Carlson; Thomas N Chase; A R Braun
D1 dopamine receptor activation required for postsynaptic expression of D2 agonist effects.
Science (New York, N.Y.) 1987;236(4802):719-22.
1987: Giovanni Fabbrini; Jorge L Juncos; M Maral Mouradian; C Serrati; Thomas N Chase
3-O-methyldopa and motor fluctuations in Parkinson's disease.
Neurology 1987;37(5):856-9.
1987: Giovanni Fabbrini; Jorge L Juncos; M Maral Mouradian; C Serrati; Thomas N Chase
Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease.
Annals of neurology 1987;21(4):370-6.
1987: Jorge L Juncos; Giovanni Fabbrini; M Maral Mouradian; C Serrati; A M Kask; Thomas N Chase
Controlled release levodopa treatment of motor fluctuations in Parkinson's disease.
Journal of neurology, neurosurgery, and psychiatry 1987;50(2):194-8.
1987: Thomas N Chase; Jorge L Juncos; C Serrati; Giovanni Fabbrini; G Bruno
Fluctuation in response to chronic levodopa therapy: pathogenetic and therapeutic considerations.
Advances in neurology 1987;45():477-80.
1987: A Braun; Giovanni Fabbrini; M Maral Mouradian; C Serrati; P Barone; Thomas N Chase
Selective D-1 dopamine receptor agonist treatment of Parkinson's disease.
Journal of neural transmission 1987;68(1-2):41-50.
1987: Carol A Tamminga; N L Foster; P Fedio; E D Bird; Thomas N Chase
Alzheimer's disease: low cerebral somatostatin levels correlate with impaired cognitive function and cortical metabolism.
Neurology 1987;37(1):161-5.
1987: Carol A Tamminga; K Tanimoto; S Kuo; Thomas N Chase; P C Contreras; K C Rice; A E Jackson; T L O'Donohue
PCP-induced alterations in cerebral glucose utilization in rat brain: blockade by metaphit, a PCP-receptor-acylating agent.
Synapse (New York, N.Y.) 1987;1(5):497-504.
1986: A R Braun; Thomas N Chase
Obligatory D-1/D-2 receptor interaction in the generation of dopamine agonist related behaviors.
European journal of pharmacology 1986;131(2-3):301-6.
1986: M M Mouradian; J M Farah; E Mohr; G Fabbrini; T L O'Donohue; Thomas N Chase
Spinal fluid CRF reduction in Alzheimer's disease.
Neuropeptides 1986;8(4):393-400.
1986: A Martin; P Brouwers; F Lalonde; Christiane Sylvia Cox; P Teleska; P Fedio; N L Foster; Thomas N Chase
Towards a behavioral typology of Alzheimer's patients.
Journal of clinical and experimental neuropsychology 1986;8(5):594-610.
1986: Ted M Dawson; P Barone; A Sidhu; J K Wamsley; Thomas N Chase
Quantitative autoradiographic localization of D-1 dopamine receptors in the rat brain: use of the iodinated ligand [125I]SCH 23982.
Neuroscience letters 1986;68(3):261-6.
1986: Clifford W Shults; L Steardo; P Barone; E Mohr; Jorge L Juncos; C Serrati; P Fedio; Carol A Tamminga; Thomas N Chase
Huntington's disease: effect of cysteamine, a somatostatin-depleting agent.
Neurology 1986;36(8):1099-102.
1986: G Bruno; E Mohr; M Gillespie; P Fedio; Thomas N Chase
Muscarinic agonist therapy of Alzheimer's disease. A clinical trial of RS-86.
Archives of neurology 1986;43(7):659-61.
1986: P Barone; T A Davis; A R Braun; Thomas N Chase
Dopaminergic mechanisms and motor function: characterization of D-1 and D-2 dopamine receptor interactions.
European journal of pharmacology 1986;123(1):109-14.
1986: D Naber; Daniel R Weinberger; M Bullinger; M Polsby; Thomas N Chase
[Spasmodic torticollis. A study of symptoms, course, family history and psychopathology].
Der Nervenarzt 1986;57(4):238-43.
1986: K Schlesinger; M A Pelleymounter; J van de Kamp; D L Bader; J M Stewart; Thomas N Chase
Substance P facilitation of memory: effects in an appetitively motivated learning task.
Behavioral and neural biology 1986;45(2):230-9.
1986: C S Irving; L Marks; PD Klein; N Foster; P L Gadde; Thomas N Chase; D Samuel
New evidence for taurine biosynthesis in man obtained from 18O2 inhalation studies.
Life sciences 1986;38(6):491-5.
1986: N L Foster; Thomas N Chase; N J Patronas; M M Gillespie; P Fedio
Cerebral mapping of apraxia in Alzheimer's disease by positron emission tomography.
Annals of neurology 1986;19(2):139-43.
1986: N Foster; Thomas N Chase
Cerebral metabolic rate of glucose and Alzheimer's disease.
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 1986;6(1):125-7.
1986: N L Foster; Carol A Tamminga; T L O'Donohue; K Tanimoto; E D Bird; Thomas N Chase
Brain choline acetyltransferase activity and neuropeptide Y concentrations in Alzheimer's disease.
Neuroscience letters 1986;63(1):71-5.
1986: Carol A Tamminga; R L Littman; L D Alphs; Thomas N Chase; Gunvant K Thaker; A M Wagman
Neuronal cholecystokinin and schizophrenia: pathogenic and therapeutic studies.
Psychopharmacology 1986;88(3):387-91.
1986: P Barone; A R Braun; Thomas N Chase
D-1/D-2 dopamine receptor interactions in the regulation of extrapyramidal motor function: studies in animal models and parkinsonian patients.
Clinical neuropharmacology 1986;9 Suppl 4():128-30.
1986: A R Braun; P Barone; Thomas N Chase
Interaction of D1 and D2 dopamine receptors in the expression of dopamine agonist induced behaviors.
Advances in experimental medicine and biology 1986;204():151-66.
1986: J T Simmons; B Pastakia; Thomas N Chase; Clifford W Shults
Magnetic resonance imaging in Huntington disease.
AJNR. American journal of neuroradiology 1986;7(1):25-8.
1986: Thomas N Chase; V Geoffrey; M Gillespie; G H Burrows
Structural and functional studies of Gilles de la Tourette syndrome.
Revue neurologique 1986;142(11):851-5.
1986: C L Ludwig; Daniel R Weinberger; G Bruno; M Gillespie; K Bakker; Peter LeWitt; Thomas N Chase
Buspirone, Parkinson's disease, and the locus ceruleus.
Clinical neuropharmacology 1986;9(4):373-8.
1986: E Mohr; G Bruno; N Foster; M Gillespie; Christiane Sylvia Cox; T A Hare; Carol A Tamminga; P Fedio; Thomas N Chase
GABA-agonist therapy for Alzheimer's disease.
Clinical neuropharmacology 1986;9(3):257-63.
1985: Carol A Tamminga; N L Foster; Thomas N Chase
Reduced brain somatostatin levels in Alzheimer's disease.
The New England journal of medicine 1985;313(20):1294-5.
1985: S L Cohen; M Knight; Carol A Tamminga; Thomas N Chase
A comparison of peripheral and central effects of CCK8 on water-reinforced operant responding.
European journal of pharmacology 1985;116(3):229-38.
1985: V J Massari; Clifford W Shults; C H Park; Y Tizabi; T W Moody; B M Chronwall; M Culver; Thomas N Chase
Deafferentation causes a loss of presynaptic bombesin receptors and supersensitivity of substance P receptors in the dorsal horn of the cat spinal cord.
Brain research 1985;343(2):268-74.
1985: L Steardo; M Knight; Carol A Tamminga; P Barone; A M Kask; Thomas N Chase
CCK26-33 degrading activity in brain and nonneural tissue: a metalloendopeptidase.
Journal of neurochemistry 1985;45(3):784-90.
1985: Jorge L Juncos; C Serrati; G Fabbrini; Thomas N Chase
Fluctuating levodopa concentrations and Parkinson's disease.
Lancet 1985;2(8452):440.
1985: Clifford W Shults; H Yajima; H G Gullner; Thomas N Chase; T L O'Donohue
Demonstration and distribution of kassinin-like material (substance K) in the rat central nervous system.
Journal of neurochemistry 1985;45(2):552-8.
1985: M Knight; P Barone; Carol A Tamminga; L Steardo; Thomas N Chase
Cholecystokinin octapeptide analogues stable to brain proteolysis.
Peptides 1985;6(4):631-4.
1985: Carol A Tamminga; Peter LeWitt; Thomas N Chase
Cholecystokinin and neurotensin gradients in human CSF.
Archives of neurology 1985;42(4):354-5.
1985: L Steardo; M Knight; Carol A Tamminga; Thomas N Chase
Products of cholecystokinin (CCK)-octapeptide proteolysis interact with central CCK receptors.
Neuroscience letters 1985;54(2-3):319-25.
1985: Clifford W Shults; S H Buck; E Burcher; Thomas N Chase; T L O'Donohue
Distinct binding sites for substance P and neurokinin A (substance K): co-transmitters in rat brain.
Peptides 1985;6(2):343-5.
1985: L Steardo; P Monteleone; Carol A Tamminga; P L Canonico; D Denman; U Scapagnini; Thomas N Chase
Differential responses in prolactin levels induced by naloxone in humans.
Psychoneuroendocrinology 1985;10(2):203-9.
1985: R P Newman; Peter LeWitt; Clifford W Shults; G Bruno; N L Foster; Thomas N Chase; Donald B Calne
Dystonia: treatment with bromocriptine.
Clinical neuropharmacology 1985;8(4):328-33.
1985: G Bruno; S Ruggieri; Thomas N Chase; K Bakker; Carol A Tamminga
Caerulein treatment of Parkinson's disease.
Clinical neuropharmacology 1985;8(3):266-70.
1985: Thomas N Chase; P Barone; G Bruno; S L Cohen; Jorge L Juncos; M Knight; S Ruggeri; L Steardo; Carol A Tamminga
Cholecystokinin-mediated synaptic function and the treatment of neuropsychiatric disease.
Annals of the New York Academy of Sciences 1985;448():553-61.
1985: R P Newman; Carol A Tamminga; Thomas N Chase; Peter LeWitt
EMD 23,448: effects of a putative dopamine autoreceptor agonist in chorea.
Journal of neural transmission 1985;61(1-2):125-9.
1985: Carol A Tamminga; Gunvant K Thaker; Thomas N Chase
GABA dysfunction in the pathophysiology of tardive dyskinesia.
Psychopharmacology. Supplementum 1985;2():122-7.
1984: B M Chronwall; Thomas N Chase; T L O'Donohue
Coexistence of neuropeptide Y and somatostatin in rat and human cortical and rat hypothalamic neurons.
Neuroscience letters 1984;52(3):213-7.
1984: N L Foster; Thomas N Chase; L Mansi; R Brooks; P Fedio; N J Patronas; G Di Chiro
Cortical abnormalities in Alzheimer's disease.
Annals of neurology 1984;16(6):649-54.
1984: Thomas N Chase; P Fedio; N L Foster; R Brooks; G Di Chiro; L Mansi
Wechsler Adult Intelligence Scale performance. Cortical localization by fluorodeoxyglucose F 18-positron emission tomography.
Archives of neurology 1984;41(12):1244-7.
1984: T L O'Donohue; V J Massari; Chistopher Pazoles; B M Chronwall; Clifford W Shults; R Quirion; Thomas N Chase; T W Moody
A role for bombesin in sensory processing in the spinal cord.
The Journal of neuroscience : the official journal of the Society for Neuroscience 1984;4(12):2956-62.
1984: Clifford W Shults; R Quirion; B Chronwall; Thomas N Chase; T L O'Donohue
A comparison of the anatomical distribution of substance P and substance P receptors in the rat central nervous system.
Peptides 1984;5(6):1097-128.
1984: N L Foster; R P Newman; Peter LeWitt; M M Gillespie; T A Larsen; Thomas N Chase
Peripheral beta-adrenergic blockade treatment of parkinsonian tremor.
Annals of neurology 1984;16(4):505-8.
1984: N L Foster; R P Newman; Peter LeWitt; M M Gillespie; Thomas N Chase
Treatment of resting tremor by beta-adrenergic blockade.
American heart journal 1984;108(4 Pt 2):1173-7.
1984: M Knight; Carol A Tamminga; L Steardo; M E Beck; P Barone; Thomas N Chase
Cholecystokinin-octapeptide fragments: binding to brain cholecystokinin receptors.
European journal of pharmacology 1984;105(1-2):49-55.
1984: M Knight; Carol A Tamminga; Y Ito; J D Gardner; Thomas N Chase
Purification of a cholecystokinin fragment peptide in the horizontal flow-through coil planet centrifuge.
Journal of chromatography 1984;301(1):277-81.
1984: E Burcher; Clifford W Shults; S H Buck; Thomas N Chase; T L O'Donohue
Autoradiographic distribution of substance K binding sites in rat gastrointestinal tract: a comparison with substance P.
European journal of pharmacology 1984;102(3-4):561-2.
1984: C J Helke; Clifford W Shults; Thomas N Chase; T L O'Donohue
Autoradiographic localization of substance P receptors in rat medulla: effect of vagotomy and nodose ganglionectomy.
Neuroscience 1984;12(1):215-23.
1984: J R Keeler; Clifford W Shults; Thomas N Chase; C J Helke
The ventral surface of the medulla in the rat: pharmacologic and autoradiographic localization of GABA-induced cardiovascular effects.
Brain research 1984;297(2):217-24.
1984: alessandro denaro; Carol A Tamminga; S Ruggieri; Thomas N Chase; A Agnoli
State of DA/ACh balance after chronic treatment with haloperidol and with THIP in rats.
Advances in neurology 1984;40():141-7.
1984: Thomas N Chase; N L Foster; P Fedio; R Brooks; L Mansi; R Kessler; G Di Chiro
Gilles de la tourette syndrome: studies with the fluorine-18-labeled fluorodeoxyglucose positron emission tomographic method.
Annals of neurology 1984;15 Suppl():S175.
1984: Thomas N Chase; N L Foster; P Fedio; R Brooks; L Mansi; G Di Chiro
Regional cortical dysfunction in Alzheimer's disease as determined by positron emission tomography.
Annals of neurology 1984;15 Suppl():S170-4.
1984: Thomas N Chase; N L Foster; P Fedio; L Mansi; R Brooks; R Kessler; G Di Chiro
Cognitive and cerebral metabolic function in early and advanced Alzheimer's disease.
Monographs in neural sciences 1984;11():176-9.
1983: R Durso; Carol A Tamminga; S Ruggeri; alessandro denaro; S Kuo; Thomas N Chase
Twenty-four hour plasma levels of growth hormone and prolactin in Huntington's disease.
Journal of neurology, neurosurgery, and psychiatry 1983;46(12):1134-7.
1983: H Doi; K M Chen; Thomas N Chase; R T Yanagihara; Y Uebayashi
[Effect of L-dopa on clinical duration and quality of life of patients with Parkinsonism-dementia in Guam].
Rinshō shinkeigaku = Clinical neurology 1983;23(11):935-42.
1983: N M Papadopoulos; Peter LeWitt; R P Newman; M I Raphaelson; Thomas N Chase
A unique protein in normal human cerebrospinal fluid.
Clinical chemistry 1983;29(10):1842-4.
1983: K Schlesinger; D U Lipsitz; P L Peck; M A Pelleymounter; J M Stewart; Thomas N Chase
Substance P enhancement of passive and active avoidance conditioning in mice.
Pharmacology, biochemistry, and behavior 1983;19(4):655-61.
1983: S L Cohen; M Knight; Carol A Tamminga; Thomas N Chase
Minimized tolerance to the suppressive effects of CCK8 on operant responding.
Behavioral and neural biology 1983;39(1):123-7.
1983: R Durso; Carol A Tamminga; alessandro denaro; S Ruggeri; Thomas N Chase
Plasma growth hormone and prolactin response to dopaminergic GABAmimetic and cholinergic stimulation in Huntington's disease.
Neurology 1983;33(9):1229-32.
1983: K Schlesinger; D U Lipsitz; P L Peck; M A Pelleymounter; J M Stewart; Thomas N Chase
Substance p reversal of electroconvulsive shock and cycloheximide-induced retrograde amnesia.
Behavioral and neural biology 1983;39(1):30-9.
1983: N L Foster; Thomas N Chase; P Fedio; N J Patronas; R A Brooks; G Di Chiro
Alzheimer's disease: focal cortical changes shown by positron emission tomography.
Neurology 1983;33(8):961-5.
1983: Thomas N Chase; N L Foster; L Mansi
Alzheimer's disease and the parietal lobe.
Lancet 1983;2(8343):225.
1983: S S Wolf; T W Moody; R Quirion; Clifford W Shults; Thomas N Chase; T L O'Donohue
Autoradiographic visualization of substance P receptors in rat brain.
European journal of pharmacology 1983;91(1):157-8.
1983: R Quirion; Clifford W Shults; T W Moody; C B Pert; Thomas N Chase; T L O'Donohue
Autoradiographic distribution of substance P receptors in rat central nervous system.
Nature 1983;303(5919):714-6.
1983: N L Foster; Thomas N Chase; alessandro denaro; T A Hare; Carol A Tamminga
THIP treatment of Huntington's disease.
Neurology 1983;33(5):637-9.
1983: N L Foster; Thomas N Chase
Diffuse involvement in progressive aphasia.
Annals of neurology 1983;13(2):224-5.
1983: S L Cohen; M Knight; Carol A Tamminga; Thomas N Chase
Tolerance to the anti-avoidance properties of cholecystokinin-octapeptide.
Peptides 1983;4(1):67-70.
1982: Clifford W Shults; R Quirion; R T Jensen; T W Moody; T L O'Donohue; Thomas N Chase
Autoradiographic localization of substance P receptors using 125I substance P.
Peptides 1982;3(6):1073-5.
1982: S L Cohen; M Knight; Carol A Tamminga; Thomas N Chase
Cholecystokinin-octapeptide effects on conditioned-avoidance behavior, stereotypy and catalepsy.
European journal of pharmacology 1982;83(3-4):213-22.
1982: R Durso; P Fedio; P Brouwers; Christiane Sylvia Cox; A J Martin; S A Ruggieri; Carol A Tamminga; Thomas N Chase
Lysine vasopressin in Alzheimer disease.
Neurology 1982;32(6):674-7.
1981: Carol A Tamminga; P J Tighe; Thomas N Chase; E G DeFraites; M H Schaffer
Des-tyrosine-gamma-endorphin administration in chronic schizophrenics. A preliminary report.
Archives of general psychiatry 1981;38(2):167-8.
1980: John G Nutt; E A Mrox; S E Leeman; A C Williams; W King Engel; Thomas N Chase
Substance P in human cerebrospinal fluid: reductions in peripheral neuropathy and autonomic dysfunction.
Neurology 1980;30(12):1280-5.
1980: A C Williams; Robert A Levine; Thomas N Chase; W Lovenberg; Donald B Calne
CFS hydroxylase cofactor levels in some neurological diseases.
Journal of neurology, neurosurgery, and psychiatry 1980;43(8):735-8.
1980: A Williams; N Papadopoulos; Thomas N Chase
Demonstration of CSF gamma-globulin banding in presenile dementia.
Neurology 1980;30(8):882-4.
1980: Carol A Tamminga; Thomas N Chase
Bromocriptine and CF 25-397 in the treatment of tardive dyskinesia.
Archives of neurology 1980;37(4):204-5.
1980: B L Beasley; John G Nutt; R W Davenport; Thomas N Chase
Treatment with tryptophan of levodopa-associated psychiatric disturbances.
Archives of neurology 1980;37(3):155-6.
1980: Thomas N Chase; Carol A Tamminga
Pharmacologic studies of tardive dyskinesia.
Advances in biochemical psychopharmacology 1980;24():457-61.
1979: Carol A Tamminga; J W Crayton; Thomas N Chase
Improvement in tardive dyskinesia after muscimol therapy.
Archives of general psychiatry 1979;36(5):595-8.
1979: Y Nagano; T Tsubaki; Thomas N Chase
Endocrinologic regulation of carbohydrate metabolism. Amyotrophic lateral sclerosis and Parkinsonism-dementia on Guam.
Archives of neurology 1979;36(4):217-20.
1978: Carol A Tamminga; A Neophytides; Thomas N Chase; Lawrence A Frohman
Stimulation of prolactin and growth hormone secretion by muscimol, a gamma-aminobutyric acid agonist.
The Journal of clinical endocrinology and metabolism 1978;47(6):1348-51.
1978: John G Nutt; A J Rosin; T Eisler; Donald B Calne; Thomas N Chase
Effect of an opiate antagonist on movement disorders.
Archives of neurology 1978;35(12):810-1.
1978: John G Nutt; A Rosin; Thomas N Chase
Treatment of Huntington disease with a cholinergic agonist.
Neurology 1978;28(10):1061-4.
1978: R L Weir; G Glaubiger; Thomas N Chase
Inhibition of fast axoplasmic transport by acrylamide.
Environmental research 1978;17(2):251-5.
1978: Y Nagano; T Tsubaki; M Miyashita; I Ebitani; Thomas N Chase
[Abnormal carbohydrate metabolism in amyotrophic lateral sclerosis and parkinsonism-dementia complex on Guam (author's transl)].
Rinshō shinkeigaku = Clinical neurology 1978;18(8):486-90.
1978: Carol A Tamminga; J W Crayton; Thomas N Chase
Muscimol: GABA agonist therapy in schizophrenia.
The American journal of psychiatry 1978;135(6):746-7.
1978: M Perlow; M H Ebert; E K Gordon; M G Ziegler; C R Lake; Thomas N Chase
The circadian variation of catecholamine metabolism in the subhuman primate.
Brain research 1978;139(1):101-13.
1977: D Pericić; J R Walters; Thomas N Chase
Effect of diazepam and pentobarbital on aminooxyacetic acid-induced accumulation on GABA.
Journal of neurochemistry 1977;29(5):839-46.
1977: N K Gartrell; Donald Lynn (Lynn) Loriaux; Thomas N Chase
Plasma testosterone in homosexual and heterosexual women.
The American journal of psychiatry 1977;134(10):1117-8.
1977: W E Lightfoote; G F Molinari; Thomas N Chase
Modification of cerebral ischemic damage by anesthetics.
Stroke; a journal of cerebral circulation 1977;8(5):627-8.
1977: MARK JACOB PERLOW; E K Gordon; M E Ebert; H J Hoffman; Thomas N Chase
The circadian variation in dopamine metabolism in the subhuman primate.
Journal of neurochemistry 1977;28(6):1381-3.
1977: MARK JACOB PERLOW; B Festoff; E K Gordon; M H Ebert; D K Johnson; Thomas N Chase
Daily fluctuation in the concentration of cAMP in the conscious primate brain.
Brain research 1977;126(2):391-6.
1977: B L Beasley; R W Davenport; Thomas N Chase
Fenfluramine hydrochloride treatment of parkinsonism.
Archives of neurology 1977;34(4):255-6.
1976: T Shetty; Thomas N Chase
Central monoamines and hyperkinase of childhood.
Neurology 1976;26(10):1000-2.
1976: R Kartzinel; M H Ebert; Thomas N Chase
Intravenous probenecid loading. Effects on plasma and cerebrospinal fluid probenecid levels and on monoamine metabolites in cerebrospinal fluid.
Neurology 1976;26(10):992-6.
1976: Thomas N Chase; N Eng; E K Gordon
Biochemical aids in the diagnosis of Parkinson's disease.
Annals of clinical and laboratory science 1976;6(1):4-10.
1976: Thomas N Chase; Ira Shoulson; A C Carter
Serotonergic functions in man.
Monographs in neural sciences 1976;3():8-14.
1976: Ira Shoulson; Thomas N Chase
Clonidine and the anti-parkinsonian response to L-DOPA or piribedil.
Neuropharmacology 1976;15(1):25-7.
1976: M Perlow; E Gordon; M Ebert; B Festoff; Thomas N Chase
The circadian pattern of catcholamine metabolites and cAMP in the cerebrospinal fluid of subhuman primates.
Transactions of the American Neurological Association 1976;101():279-80.
1976: R Kartzinel; M D Perlow; A C Carter; Thomas N Chase; Donald B Calne; Ira Shoulson
Metabolic studies with bromocriptine in patients with idiopathic parkinsonism and Huntington's chorea.
Transactions of the American Neurological Association 1976;101():53-6.
1976: Thomas N Chase
Rational approaches to the pharmacotherapy of chorea.
Research publications - Association for Research in Nervous and Mental Disease 1976;55():337-50.
1976: Ira Shoulson; R Kartzinel; Thomas N Chase
Huntington's disease: treatment with dipropylacetic acid and gamma-aminobutyric acid.
Neurology 1976;26(1):61-3.
1975: Ira Shoulson; G A Glaubiger; Thomas N Chase
On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients.
Neurology 1975;25(12):1144-8.
1975: B T Thach; Thomas N Chase; James F. Bosma
Oral facial dyskinesia accociated with prolonged use of antihistaminic decongestants.
The New England journal of medicine 1975;293(10):486-7.
1975: Ira Shoulson; Thomas N Chase; E Roberts; J N Van Balgooy
Letter: Huntington's disease: treatment with imidazole-4-acetic acid.
The New England journal of medicine 1975;293(10):504-5.
1975: Ira Shoulson; Thomas N Chase
Fenfluramine in man: hypophagia associated with diminished serotonin turnover.
Clinical pharmacology and therapeutics 1975;17(5):616-21.
1975: Thomas N Chase; Ira Shoulson
Behavioural and biochemical effects of fenfluramine in patients with neurologic disease.
Postgraduate medical journal 1975;51 Suppl 1():105-9.
1975: Thomas N Chase; Ira Shoulson
Dopaminergic mechanisms in patients with extrapyramidal disease.
Advances in neurology 1975;9():359-66.
1975: E W Pelton; Thomas N Chase
L-Dopa and the treatment of extrapyramidal disease.
Advances in pharmacology and chemotherapy 1975;13():253-304.
1975: Ira Shoulson; Thomas N Chase
Huntington's disease.
Annual review of medicine 1975;26():419-36.
1974: Ira Shoulson; Thomas N Chase
Letter: Fenfluramine and dyskinesias.
The New England journal of medicine 1974;291(16):850-1.
1974: Thomas N Chase
Fusaric acid in Parkinson's disease.
Neurology 1974;24(7):637-9.
1974: Thomas N Chase
Proceedings: Clinical studies of dopaminergic mechanisms.
Psychopharmacology bulletin 1974;10(3):43-4.
1974: Thomas N Chase; A C Woods; M A Lipton; C E Morris
Hypothalamic releasing factors and Parkinson disease.
Archives of neurology 1974;31(1):55-6.
1974: Thomas N Chase; A C Woods; G A Glaubiger
Parkinson disease treated with a suspected dopamine receptor agonist.
Archives of neurology 1974;30(5):383-6.
1974: J S Carman; Ira Shoulson; Thomas N Chase
Letter: Huntington's chorea treated with lithium carbonate.
Lancet 1974;1(7861):811.
1974: J Pérez-Cruet; Thomas N Chase; D L Murphy
Dietary regulation of brain tryptophan metabolism by plasma ratio of free tryptophan and neutral amino acids in humans.
Nature 1974;248(450):693-5.
1974: E M Holden; Jacob Brody ; Thomas N Chase
Parkinsonism-dementia of Guam: treatment with levodopa and L-alpha-methyldopahydrazine.
Neurology 1974;24(3):263-5.
1974: Thomas N Chase; T S Balch; D M Jacobowitz
Dopamine histofluorescence in post-mortem specimens of human and rat striatum.
Journal of psychiatric research 1974;11():281-2.
1974: Thomas N Chase
Clinical studies of dopaminergic mechanisms.
Advances in biochemical psychopharmacology 1974;12(0):427-34.
1974: Thomas N Chase
Serotonergic-dopaminergic interactions and extrapyramidal function.
Advances in biochemical psychopharmacology 1974;11(0):377-85.
1974: Thomas N Chase
Serotonergic mechanisms and extrapyramidal function in man.
Advances in neurology 1974;5():31-9.
1973: Thomas N Chase; E M Holden; Jacob Brody
Levodopa-induced dyskinesias. Comparison in Parkinsonism-dementia and amyotrophic lateral sclerosis.
Archives of neurology 1973;29(5):328-33.
1973: Thomas N Chase
Central monoamine metabolism in man. Effect of putative dopamine receptor agonists and antagonists.
Archives of neurology 1973;29(5):349-51.
1973: H Cramer; L K Ng; Thomas N Chase
Adenosine 3',5'-monophosphate in cerebrospinal fluid. Effect of drugs and neurologic disease.
Archives of neurology 1973;29(3):197-9.
1973: Thomas N Chase; E K Gordon; L K Ng
Norepinephrine metabolism in the central nervous system of man: studies using 3-methoxy-4-hydroxyphenylethylene glycol levels in cerebrospinal fluid.
Journal of neurochemistry 1973;21(3):581-7.
1973: A C Woods; Thomas N Chase
M.I.F.: effect on levodopa dyskinesias in man.
Lancet 1973;2(7827):513.
1973: A C Woods; G A Glaubiger; Thomas N Chase
Sustained-release levodopa.
Lancet 1973;1(7816):1391.
1973: J Fermaglich; Thomas N Chase
Methyldopa or methyldopahydrazine as levodopa synergists.
Lancet 1973;1(7814):1261-2.
1973: E K Gordon; J Oliver; F K Goodwin; Thomas N Chase; R M Post
Effect of probenecid on free 3-methoxy-4-hydroxyphenylethylene glycol (MHPG) and its sulphate in human cerebrospinal fluid.
Neuropharmacology 1973;12(4):391-6.
1973: T S Balch; Thomas N Chase; D M Jacobowitz
Dopamine histofluorescence: restoration in mammalian brain tissues prepared several hours post mortem.
Brain research 1973;52():419-23.
1973: R L Weir; Thomas N Chase; L K Ng; I J Kopin
5-hydroxyindoleacetic cid in spinal fluid: relative contribution from brain and spinal cord.
Brain research 1973;52():409-12.
1973: E F Donnelly; Thomas N Chase
Intellectual and memory function in parkinsonian and non-parkinsonian patients treated with L-dopa.
Diseases of the nervous system 1973;34(2):119-23.
1973: Thomas N Chase; D L Murphy
Serotonin and central nervous system function.
Annual review of pharmacology 1973;13():181-97.
1972: J R Mendell; D L Murphy; W King Engel; Thomas N Chase; E Gordon
Catecholamines and indoleamines in patients with Duchenne muscular dystrophy.
Archives of neurology 1972;27(6):518-20.
1972: Thomas N Chase; L K Ng
Central monoamine metabolism in Parkinson's disease.
Archives of neurology 1972;27(6):486-91.
1972: L K Ng; Thomas N Chase; R W Colburn; I J Kopin
Release of ( 3 H)dopamine by L-5-hydroxytryptophan.
Brain research 1972;45(2):499-505.
1972: Thomas N Chase
Serotonergic mechanisms in Parkinson's disease.
Archives of neurology 1972;27(4):354-6.
1972: Ira T Lott; Thomas N Chase; D L Murphy
Down's syndrome: transport, storage, and metabolism of serotonin in blood platelets.
Pediatric research 1972;6(9):730-5.
1972: Ira T Lott; D L Murphy; Thomas N Chase
Down's syndrome. Central monoamine turnover in patients with diminished platelet serotonin.
Neurology 1972;22(9):967-72.
1972: L K Ng; Thomas N Chase; R W Colburn; I J Kopin
L-dopa in Parkinsonism. A possible mechanism of action.
Neurology 1972;22(7):688-96.
1972: H Cramer; L K Ng; Thomas N Chase
Effect of probenecid on levels of cyclic AMP in human cerebrospinal fluid.
Journal of neurochemistry 1972;19(6):1601-2.
1972: Thomas N Chase; L K Ng; A M Watanabe
Parkinson's disease. Modification by 5-hydroxytryptophan.
Neurology 1972;22(5):479-84.
1972: Thomas N Chase; A M Watanabe
Methyldopahydrazine as an adjunct to L-dopa therapy in parkinsonism.
Neurology 1972;22(4):384-92.
1972: Thomas N Chase; A M Watanabe; K H Brodie; E F Donnelly
Huntington's chorea. Effect of serotonin depletion.
Archives of neurology 1972;26(3):282-4.
1972: Thomas N Chase
Drug-induced extrapyramidal disorders.
Research publications - Association for Research in Nervous and Mental Disease 1972;50():448-71.
1971: Thomas N Chase; L K Ng
Probenecid test in Parkinson's disease.
Lancet 1971;2(7736):1265-6.
1971: J A Schnur; Thomas N Chase; Jacob Brody
Parkinsonism-dementia of Guam: treatment with L-dopa.
Neurology 1971;21(12):1236-42.
1971: J L Weiss; C K Cohn; Thomas N Chase
Reduction of catechol-O-methyl-transferases activity by chronic L-dopa therapy.
Nature 1971;234(5326):218-9.
1971: J R Mendell; Thomas N Chase; W King Engel
Amyotrophic lateral sclerosis. A study of central monoamine metabolism and therapeutic trial of levodopa.
Archives of neurology 1971;25(4):320-5.
1971: R J Wyatt; Thomas N Chase; D J Kupfer; J Scott; F Snyder
Brain catecholamines and human sleep.
Nature 1971;233(5314):63-5.
1971: E S Vesell; L Ng; G T Passananti; Thomas N Chase
Inhibition of drug metabolism by levodopa in combination with a dopa-decarboxylase inhibitor.
Lancet 1971;2(7720):370.
1971: J L Weiss; L K Ng; Thomas N Chase
Long-lasting dyskinesia induced by levodopa.
Lancet 1971;1(7707):1016-7.
1971: K Y Ng; Thomas N Chase; R W Colburn; I J Kopin
Dopamine: stimulation-induced release from central neurons.
Science (New York, N.Y.) 1971;172(3982):487-9.
1971: J R Mendell; Thomas N Chase; W King Engel
Amyotrophic lateral sclerosis: metabolism of central monoamines and treatment with L-dopa.
Transactions of the American Neurological Association 1971;96():284-6.
1971: Thomas N Chase; George R Breese; E K Gordon; I J Kopin
Catecholamine metabolism in the dog: comparison of intravenously and intraventricularly administered [14C]dopamine and [3H]norepinephrine.
Journal of neurochemistry 1971;18(1):135-40.
1971: J L Weiss; Thomas N Chase
Levodopa in Parkinsonism.
Drugs 1971;2(4):257-61.
1970: R J Wyatt; Thomas N Chase; J Scott; F Snyder; K Engleman
Effect of L-dopa on the sleep of man.
Nature 1970;228(5275):999-1001.
1970: Thomas N Chase
Cerebrospinal fluid monoamine metabolites and peripheral decarboxylase inhibitors in parkinsonism.
Neurology 1970;20(12):36-40.
1970: Thomas N Chase
Cerebrospinal fluid monoamine metabolites and peripheral decarboxylase inhibitors in parkinsonism.
Neurology 1970;20(12):Suppl:36-40.
1970: Thomas N Chase
5-hydroxytryptophan in parkinsonism.
Lancet 1970;2(7681):1029-30.
1970: Thomas N Chase
Biochemical and pharmacologic studies of dystonia.
Neurology 1970;20(11):122-30.
1970: K Y Ng; Thomas N Chase; I J Kopin
Drug-induced release of 3H-norepinephrine and 3H-serotonin from brain slices.
Nature 1970;228(5270):468-9.
1970: K Y Ng; Thomas N Chase; R W Colburn; I J Kopin
L-Dopa-induced release of cerebral monoamines.
Science (New York, N.Y.) 1970;170(3953):76-7.
1970: A M Watanabe; Thomas N Chase; P V Cardon
Effect of L-dopa alone and in combination with an extracerebral decarboxylase inhibitor on blood pressure and some cardiovascular reflexes.
Clinical pharmacology and therapeutics 1970;11(5):740-6.
1970: Thomas N Chase; J A Schnur; E K Gordon
Cerebrospinal fluid monoamine catabolites in drug-induced extrapyramidal disorders.
Neuropharmacology 1970;9(3):265-8.
1970: Jacob Brody ; Thomas N Chase; E K Gordon
Depressed monoamine catabolite levels in cerebrospinal fluid of patients with parkinsonism dementia of Guam.
The New England journal of medicine 1970;282(17):947-50.
1970: J R Mendell; W King Engel; Thomas N Chase
Modification by L-dopa of a case of progressive supranuclear palsy. With evidence of defective cerebral dopamine metabolism.
Lancet 1970;1(7647):593-4.
1970: Thomas N Chase; R I Katz; I J Kopin
Effect of diazepam on fate of intracisternally injected serotonin-C14.
Neuropharmacology 1970;9(2):103-8.
1970: George R Breese; Thomas N Chase; I J Kopin
Effect of monoamine oxidase inhibitors on the disposition of intracisternally administrred metaraminol-3H.
Biochemical pharmacology 1970;19(2):525-32.
1970: R I Katz; Thomas N Chase
Neurohumoral mechanisms in the brain slice.
Advances in pharmacology and chemotherapy 1970;8():1-30.
1969: R I Katz; Thomas N Chase; I J Kopin
Effect of ions on stimulus-induced release of amino acids from mammalian brain slices.
Journal of neurochemistry 1969;16(3):961-7.
1969: W E Bunney; David S Janowsky; F K Goodwin; John M Davis; H K Brodie; D L Murphy; Thomas N Chase
Effect of L-DOPA on depression.
Lancet 1969;1(7600):885-6.
1969: Thomas N Chase; R I Katz; I J Kopin
Release of [3H]serotonin from brain slices.
Journal of neurochemistry 1969;16(4):607-15.
1969: George R Breese; Thomas N Chase; I J Kopin
Metabolism of tyramine-3H and octopamine-3H by rat brain.
Biochemical pharmacology 1969;18(4):863-9.
1969: George R Breese; Thomas N Chase; I J Kopin
Metabolism of some phenylethylamines and their beta-hydroxylated analogs in brain.
The Journal of pharmacology and experimental therapeutics 1969;165(1):9-13.
1969: Thomas N Chase; R I Katz; I J Kopin
Effect of anticonvulsants on brain serotonin.
Transactions of the American Neurological Association 1969;94():236-8.
1969: R I Katz; Thomas N Chase; I J Koplin
Electrically stimulated release of norepinephrine-H3 and serotonin-H3 from mammalian brain slices: a model for studying the effects of drugs on putative central neurotransmitters.
Transactions of the American Neurological Association 1969;94():284-6.
1968: R I Katz; Thomas N Chase; I J Kopin
Evoked release of norepinephrine and serotonin from brain slices: inhibitoon by lithium.
Science (New York, N.Y.) 1968;162(3852):466-7.
1968: Thomas N Chase; L Moretti; A L Prensky
Clinical and electroencephalographic manifestations of vascular lesions of the pons.
Neurology 1968;18(4):357-68.
1968: Thomas N Chase; N P Rosman; Donald L Price
The cerebral syndromes associated with dissecting aneurysm of the aorta. A clinicopathological study.
Brain : a journal of neurology 1968;91(1):173-90.
1968: Thomas N Chase; I J Kopin
Stimulus-induced release of substances from olfactory bulb using the push-pull cannula.
Nature 1968;217(5127):466-7.
1968: Thomas N Chase; George R Breese; D O Carpenter; S M Schanberg; I J Kopin
Stimulation-induced release of serotonin.
Advances in pharmacology 1968;6(Pt A):351-64.
1967: Thomas N Chase; George R Breese; I J Kopin
Serotonin release from brain slices by electrical stimulation: regional differences and effect of LSD.
Science (New York, N.Y.) 1967;157(3795):1461-3.